Traws Pharma Inc. (NASDAQ: TRAW) on Wednesday shared interim data from an ongoing randomized, open-label Phase 2 with ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor.

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

Jason Fernando is a professional investor and writer who enjoys tackling and communicating complex business and financial problems. The market approach is a method for determining the value of an ...

Simplist is an online marketplace of mortgage lenders; human guidance is optional. You’ll make payments to a loan servicer, not to Simplist. Loans are not available in every state. Loan origination ...

Apple's latest phone has a lot in common with the previous model, but there are notable improvements to the camera, display and battery. Is it worth the upgrade? Abrar's interests include phones, ...

Amica, State Farm and USAA offer some of the best home and auto insurance bundles, according to our analysis. Many, or all, of the products featured on this page are from our advertising partners who ...

Jeff Carlson writes about mobile technology for CNET. He is also the author of dozens of how-to books covering a wide spectrum ranging from Apple devices and cameras to photo editing software and ...

Brooks and Atkins Stohr on Trump's return and its impact on the country New York Times columnist David Brooks and Kimberly Atkins Stohr of the Boston Globe join William Brangham to discuss the year in ...